NCT05346042: SCIP-COVID19

Safe and Timely Cessation of Isolation of Patients With COVID-19 (The SCIP-COVID-19) Study

Active, enrolled Last updated 5 March 2025

What this trial tests

trial testing duration infectiousness in COVID-19 in 7,000 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

1 December 2022

Primary endpoint
1 February 2025

31 December 2025

Quick facts

Lead sponsor	Anne Voor in 't holt
Status	Active, enrolled
Study type	OBSERVATIONAL
Enrollment	7,000
Start date	1 December 2022
Primary completion	1 February 2025
Estimated completion	31 December 2025
Sites	1 location across Netherlands

Drugs / interventions tested

• duration infectiousness

Conditions studied

• COVID-19 — all drugs for COVID-19 →

Sponsor

Anne Voor in 't holt

Who can join

18 and older, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Rationale:

In the treatment, care and isolation of COVID-19 patients, one of the most important issues is determining the duration of infectiousness. The current Dutch guideline advises at least 14 days of isolation for seriously ill patients, which is the case for most admitted patients, and at least 21 days for intubated patients. It is believed that in most cases this isolation duration is too long, which is highly undesirable for patients staying in closed single-occupancy rooms. This is known to result in limited contact with healthcare workers (HCW) and to be associated with a higher level of depression among patients. The longer the isolation, the higher the workload for HCW and the higher the costs (e.g. with about 0.5 million admission days in the Netherlands, these work out at about €14 million on personal protective equipment \[PPE\] and cleaning alone). Additionally, isolation demands a larger healthcare workforce, yielding less capacity to provide other care to non-COVID-19 patients, with numerous other consequences. On the other hand, it is possible that some patients were discontinued from isolation too early, leading to a risk of transmission to other patients and to HCW. In conclusion, duration of isolation should be as short as possible for proper patient flow and to avoid unnecessary burden to patients and HCW, and thus to healthcare in general. Therefore, there is an urgent need to define the period of infectiousness of COVID-19. We will develop a safe and effective algorithm for decision on timely discontinuation of isolation of COVID-19 hospitalized patients.

Objective:

The ultimate goal of this project is to produce new evidence-based criteria for the termination of isolation of hospitalized COVID-19 patients that are safe (very low subsequent risk of transmission to other patients or healthcare workers) while reducing the number of unnecessary days in isolation (thereby improving quality of life of patients, reducing hospital costs, and making optimal use of the scarce number of isolation beds). Multiple sources of data and evidence will be integrated to arrive at these new criteria.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.